B-cell receptor specific for Influenza A virus H5N1 hemagglutinin and neuraminidase (H5N1 HA/NA BCR)

B-cell receptors (BCRs) specific for H5N1 hemagglutinin (HA) and neuraminidase (NA) epitopes are specialized membrane-bound immunoglobulins that serve as the primary sensors for the immune system to detect the highly pathogenic H5N1 avian influenza virus (Citations: [1] PubMed, PMID: 25653225). These receptors recognize specific molecular patterns on the viral surface proteins; HA-specific BCRs typically target the globular head or the conserved stem of the hemagglutinin to block viral entry, while NA-specific BCRs target the neuraminidase enzyme to prevent viral egress (Citations: [2] Nature Reviews Immunology, 2018). Engagement of these BCRs by viral antigens or vaccines triggers B-cell activation, leading to the production of neutralizing antibodies and the establishment of immunological memory (Citations: [3] NIH/NIAID). In therapeutic development, these receptors are the intended targets of H5N1 vaccines, such as Audenz, which aim to elicit a protective immune response before exposure (Citations: [4] FDA Label, 2020). Furthermore, the identification and cloning of high-affinity BCRs from survivors have enabled the development of monoclonal antibody therapies, like MEDI8852, that can be used to treat severe cases of H5N1 infection (Citations: [5] Cell, 2016). Understanding the epitope specificity of these receptors is crucial for the design of universal influenza vaccines that can provide broad protection against multiple H5N1 clades and other emerging avian influenza strains.

Other names

H5N1-specific B-cell receptorAnti-H5N1 BCRHemagglutinin-specific B-cell receptorNeuraminidase-specific B-cell receptorH5N1 HA/NA-specific BCR

Vaccines act as antigenic stimuli that bind to and cross-link these receptors, initiating B-cell receptor signaling and subsequent differentiation into plasma cells. Monoclonal antibodies derived from these receptors bind to viral HA or NA proteins to neutralize infectivity or inhibit viral release.